PMID- 24653824
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140624
LR  - 20220330
IS  - 2008-2010 (Print)
IS  - 2008-322X (Electronic)
IS  - 2008-322X (Linking)
VI  - 8
IP  - 4
DP  - 2013 Oct
TI  - Polypoidal choroidal vasculopathy: an update on therapeutic approaches.
PG  - 359-71
AB  - Polypoidal choroidal vasculopathy (PCV) is a retinal disease involving the 
      choroidal vasculature characterized by the presence of polypoidal lesions with or 
      without branching vascular network best seen on indocyanine green angiography 
      (ICGA). Clinical features of PCV include recurrent subretinal hemorrhage; 
      serosanguineous pigment epithelial detachment, subretinal exudation and serous 
      retinal detachment. PCV is more prevalent among Asians and Blacks as compared to 
      Caucasians and has been found to account for 25 to 50% of cases of presumed 
      neovascular age-related macular degeneration in Asian patients. Treatment is 
      indicated in patients with symptomatic PCV due to potentially irreversible visual 
      loss. Various treatment modalities for symptomatic PCV have been described in the 
      literature, including thermal laser photocoagulation, ICGA-guided photodynamic 
      therapy (PDT) with verteporfin, anti-vascular endothelial growth factor (VEGF) 
      therapy, and combined PDT and anti-VEGF therapy. This review aims to provide an 
      update on the therapeutic options for PCV, with particular reference to recent 
      studies published in the past two years.
FAU - Wong, Raymond L M
AU  - Wong RL
AD  - Department of Ophthalmology & Visual Sciences, Chinese University of Hong Kong, 
      Hong Kong, People's Republic of China.
FAU - Lai, Timothy Y Y
AU  - Lai TY
AD  - Department of Ophthalmology & Visual Sciences, Chinese University of Hong Kong, 
      Hong Kong, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - J Ophthalmic Vis Res
JT  - Journal of ophthalmic & vision research
JID - 101497643
PMC - PMC3957043
OTO - NOTNLM
OT  - Anti-VEGF Therapy
OT  - Bevacizumab
OT  - Photodynamic Therapy
OT  - Polypoidal Choroidal Vasculopathy
OT  - Ranibizumab
OT  - Verteporfin
EDAT- 2014/03/22 06:00
MHDA- 2014/03/22 06:01
PMCR- 2013/10/01
CRDT- 2014/03/22 06:00
PHST- 2013/06/09 00:00 [received]
PHST- 2013/07/06 00:00 [accepted]
PHST- 2014/03/22 06:00 [entrez]
PHST- 2014/03/22 06:00 [pubmed]
PHST- 2014/03/22 06:01 [medline]
PHST- 2013/10/01 00:00 [pmc-release]
AID - JOVR-08-359 [pii]
PST - ppublish
SO  - J Ophthalmic Vis Res. 2013 Oct;8(4):359-71.